Loading…

Issues associated with residual cell-substrate DNA in viral vaccines

The presence of some residual cellular DNA derived from the production-cell substrate in viral vaccines is inevitable. Whether this DNA represents a safety concern, particularly if the cell substrate is derived from a tumor or is tumorigenic, is unknown. DNA has two biological activities that need t...

Full description

Saved in:
Bibliographic Details
Published in:Biologicals 2009-06, Vol.37 (3), p.190-195
Main Authors: Sheng-Fowler, Li, Lewis, Andrew M., Peden, Keith
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653
cites cdi_FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653
container_end_page 195
container_issue 3
container_start_page 190
container_title Biologicals
container_volume 37
creator Sheng-Fowler, Li
Lewis, Andrew M.
Peden, Keith
description The presence of some residual cellular DNA derived from the production-cell substrate in viral vaccines is inevitable. Whether this DNA represents a safety concern, particularly if the cell substrate is derived from a tumor or is tumorigenic, is unknown. DNA has two biological activities that need to be considered. First, DNA can be oncogenic; second, DNA can be infectious. As part of our studies to assess the risk of residual cell-substrate DNA in viral vaccines, we have established assays that can quantify the biological activities of DNA. From data obtained using these assays, we have estimated the risk of an oncogenic or an infectious event from DNA. Because these estimates were derived from the most sensitive assays identified so far, they likely represent worst-case estimates. In addition, methods that inactivate the biological activities of DNA can be assessed and estimations of risk reduction by these treatments can be made. In this paper, we discuss our approaches to address potential safety issues associated with residual cellular DNA from neoplastic cell substrates in viral vaccines, summarize the development of assays to quantify the oncogenic and infectivity activities of DNA, and discuss methods to reduce the biological activities of DNA.
doi_str_mv 10.1016/j.biologicals.2009.02.015
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67276176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1045105609000293</els_id><sourcerecordid>67276176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653</originalsourceid><addsrcrecordid>eNqNkE1PwzAMhiME4mPwF1C5cGtxsiZpj2h8SggucI7SxIVM3QpxO8S_J9MmwQ1OtuTH9quHsTMOBQeuLuZFE_qufw3OdlQIgLoAUQCXO-yQQy3zaipgd92XMucg1QE7IpoDcF7qcp8d8FpUsqrEIbu6JxqRMkvUu2AH9NlnGN6yiBT8aLvMYdflNDY0xDTNrh4vs7DMViGm2co6F5ZIx2yvTUnwZFsn7OXm-nl2lz883d7PLh9yV4Iacj3l3tagpU0ZZTkF6VxbW-RoHVeVlUJagb5G7VvtsWldo1EJIRGFVkpOJ-x8c_c99h8p9WAWgdYB7RL7kYzSieNa_QkKUKKCChJYb0AXe6KIrXmPYWHjl-Fg1q7N3PxybdauDQiTXKfd0-2TsVmg_9ncyk3AbANgcrIKGA25gEuHPkR0g_F9-Mebb5xIlkU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20628080</pqid></control><display><type>article</type><title>Issues associated with residual cell-substrate DNA in viral vaccines</title><source>ScienceDirect Journals</source><creator>Sheng-Fowler, Li ; Lewis, Andrew M. ; Peden, Keith</creator><creatorcontrib>Sheng-Fowler, Li ; Lewis, Andrew M. ; Peden, Keith</creatorcontrib><description>The presence of some residual cellular DNA derived from the production-cell substrate in viral vaccines is inevitable. Whether this DNA represents a safety concern, particularly if the cell substrate is derived from a tumor or is tumorigenic, is unknown. DNA has two biological activities that need to be considered. First, DNA can be oncogenic; second, DNA can be infectious. As part of our studies to assess the risk of residual cell-substrate DNA in viral vaccines, we have established assays that can quantify the biological activities of DNA. From data obtained using these assays, we have estimated the risk of an oncogenic or an infectious event from DNA. Because these estimates were derived from the most sensitive assays identified so far, they likely represent worst-case estimates. In addition, methods that inactivate the biological activities of DNA can be assessed and estimations of risk reduction by these treatments can be made. In this paper, we discuss our approaches to address potential safety issues associated with residual cellular DNA from neoplastic cell substrates in viral vaccines, summarize the development of assays to quantify the oncogenic and infectivity activities of DNA, and discuss methods to reduce the biological activities of DNA.</description><identifier>ISSN: 1045-1056</identifier><identifier>EISSN: 1095-8320</identifier><identifier>DOI: 10.1016/j.biologicals.2009.02.015</identifier><identifier>PMID: 19285882</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Algorithms ; DNA - physiology ; Infectious DNA ; Oncogenic DNA ; Risk evaluation ; Viral Vaccines</subject><ispartof>Biologicals, 2009-06, Vol.37 (3), p.190-195</ispartof><rights>2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653</citedby><cites>FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19285882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheng-Fowler, Li</creatorcontrib><creatorcontrib>Lewis, Andrew M.</creatorcontrib><creatorcontrib>Peden, Keith</creatorcontrib><title>Issues associated with residual cell-substrate DNA in viral vaccines</title><title>Biologicals</title><addtitle>Biologicals</addtitle><description>The presence of some residual cellular DNA derived from the production-cell substrate in viral vaccines is inevitable. Whether this DNA represents a safety concern, particularly if the cell substrate is derived from a tumor or is tumorigenic, is unknown. DNA has two biological activities that need to be considered. First, DNA can be oncogenic; second, DNA can be infectious. As part of our studies to assess the risk of residual cell-substrate DNA in viral vaccines, we have established assays that can quantify the biological activities of DNA. From data obtained using these assays, we have estimated the risk of an oncogenic or an infectious event from DNA. Because these estimates were derived from the most sensitive assays identified so far, they likely represent worst-case estimates. In addition, methods that inactivate the biological activities of DNA can be assessed and estimations of risk reduction by these treatments can be made. In this paper, we discuss our approaches to address potential safety issues associated with residual cellular DNA from neoplastic cell substrates in viral vaccines, summarize the development of assays to quantify the oncogenic and infectivity activities of DNA, and discuss methods to reduce the biological activities of DNA.</description><subject>Algorithms</subject><subject>DNA - physiology</subject><subject>Infectious DNA</subject><subject>Oncogenic DNA</subject><subject>Risk evaluation</subject><subject>Viral Vaccines</subject><issn>1045-1056</issn><issn>1095-8320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkE1PwzAMhiME4mPwF1C5cGtxsiZpj2h8SggucI7SxIVM3QpxO8S_J9MmwQ1OtuTH9quHsTMOBQeuLuZFE_qufw3OdlQIgLoAUQCXO-yQQy3zaipgd92XMucg1QE7IpoDcF7qcp8d8FpUsqrEIbu6JxqRMkvUu2AH9NlnGN6yiBT8aLvMYdflNDY0xDTNrh4vs7DMViGm2co6F5ZIx2yvTUnwZFsn7OXm-nl2lz883d7PLh9yV4Iacj3l3tagpU0ZZTkF6VxbW-RoHVeVlUJagb5G7VvtsWldo1EJIRGFVkpOJ-x8c_c99h8p9WAWgdYB7RL7kYzSieNa_QkKUKKCChJYb0AXe6KIrXmPYWHjl-Fg1q7N3PxybdauDQiTXKfd0-2TsVmg_9ncyk3AbANgcrIKGA25gEuHPkR0g_F9-Mebb5xIlkU</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Sheng-Fowler, Li</creator><creator>Lewis, Andrew M.</creator><creator>Peden, Keith</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>Issues associated with residual cell-substrate DNA in viral vaccines</title><author>Sheng-Fowler, Li ; Lewis, Andrew M. ; Peden, Keith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Algorithms</topic><topic>DNA - physiology</topic><topic>Infectious DNA</topic><topic>Oncogenic DNA</topic><topic>Risk evaluation</topic><topic>Viral Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng-Fowler, Li</creatorcontrib><creatorcontrib>Lewis, Andrew M.</creatorcontrib><creatorcontrib>Peden, Keith</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biologicals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng-Fowler, Li</au><au>Lewis, Andrew M.</au><au>Peden, Keith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Issues associated with residual cell-substrate DNA in viral vaccines</atitle><jtitle>Biologicals</jtitle><addtitle>Biologicals</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>37</volume><issue>3</issue><spage>190</spage><epage>195</epage><pages>190-195</pages><issn>1045-1056</issn><eissn>1095-8320</eissn><abstract>The presence of some residual cellular DNA derived from the production-cell substrate in viral vaccines is inevitable. Whether this DNA represents a safety concern, particularly if the cell substrate is derived from a tumor or is tumorigenic, is unknown. DNA has two biological activities that need to be considered. First, DNA can be oncogenic; second, DNA can be infectious. As part of our studies to assess the risk of residual cell-substrate DNA in viral vaccines, we have established assays that can quantify the biological activities of DNA. From data obtained using these assays, we have estimated the risk of an oncogenic or an infectious event from DNA. Because these estimates were derived from the most sensitive assays identified so far, they likely represent worst-case estimates. In addition, methods that inactivate the biological activities of DNA can be assessed and estimations of risk reduction by these treatments can be made. In this paper, we discuss our approaches to address potential safety issues associated with residual cellular DNA from neoplastic cell substrates in viral vaccines, summarize the development of assays to quantify the oncogenic and infectivity activities of DNA, and discuss methods to reduce the biological activities of DNA.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19285882</pmid><doi>10.1016/j.biologicals.2009.02.015</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1045-1056
ispartof Biologicals, 2009-06, Vol.37 (3), p.190-195
issn 1045-1056
1095-8320
language eng
recordid cdi_proquest_miscellaneous_67276176
source ScienceDirect Journals
subjects Algorithms
DNA - physiology
Infectious DNA
Oncogenic DNA
Risk evaluation
Viral Vaccines
title Issues associated with residual cell-substrate DNA in viral vaccines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A58%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Issues%20associated%20with%20residual%20cell-substrate%20DNA%20in%20viral%20vaccines&rft.jtitle=Biologicals&rft.au=Sheng-Fowler,%20Li&rft.date=2009-06-01&rft.volume=37&rft.issue=3&rft.spage=190&rft.epage=195&rft.pages=190-195&rft.issn=1045-1056&rft.eissn=1095-8320&rft_id=info:doi/10.1016/j.biologicals.2009.02.015&rft_dat=%3Cproquest_cross%3E67276176%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-731da9075a09554305ccf9ae1eac168a525a2ed9e7df7debfcb7e6225ee276653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20628080&rft_id=info:pmid/19285882&rfr_iscdi=true